Abstract: FR-PO656
Associations Between Biomarkers of Complement Activation, Galactose-Deficient IgA1 Antibody, and the Updated Oxford Pathology Classification of IgA Nephropathy
Session Information
- Glomerular Diseases: Clinical, Outcomes, Trials - II
November 04, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1303 Glomerular Diseases: Clinical‚ Outcomes‚ and Trials
Authors
- Juan, Yunting, Far Eastern Memorial Hospital, New Taipei City, Taiwan
- Chiu, Yen-Ling, Far Eastern Memorial Hospital, New Taipei City, Taiwan
Background
Our prior study indicates a close relationship between alternative complement pathway activation, Galactose-Deficient IgA1 (Gd-IgA1) concentration, and clinical severity of IgA nephropathy (IgAN). Nonetheless, the relationship between complement factors and the updated Oxford classification of IgAN remains unclear.
Methods
This study enrolled eighty-four previously-untreated, biopsy-diagnosed IgAN patients from two medical centers in Taiwan. The clinical and laboratory findings were collected at the time of biopsy. Plasma levels of complement factor C5a, factor Ba and Gd-IgA1 were measured and analyzed.
Results
It was found that levels of proteinuria positively correlated with the updated Oxford classification of mesangial hypercellularity (M), endocapillary hypercellularity (E), tubular atrophy/interstitial fibrosis (T), and crescents (C). In addition, plasma Gd-IgA1 titer was significantly elevated in IgAN patients with tubular atrophy/interstitial fibrosis (T). Factor Ba, a biomarker of the alternative pathway, is also significantly elevated in IgAN patients with tubular atrophy/interstitial fibrosis (T). A similar change was detected for factor C5a but the difference did not reach statistical significance. Levels of factor Ba also negatively correlated with eGFR and positively correlated with proteinuria.
Conclusion
The results indicate that both levels of Gd-IgA1 antibody and factor Ba reflect the Oxford classification on IgAN. Whether these biomarkers can be used to guide therapeutic decisions requires further study.